
Sabrina Oliveira

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5272701/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Effect of Microbubble-Assisted Ultrasound on Molecular Permeability across Cell Barriers. Pharmaceutics, 2022, 14, 494.	4.5	6
2	Gold Nanoclusters: Imaging, Therapy, and Theranostic Roles in Biomedical Applications. Bioconjugate Chemistry, 2022, 33, 4-23.	3.6	57
3	In Vitro Assessment of Binding Affinity, Selectivity, Uptake, Intracellular Degradation, and Toxicity of Nanobody-Photosensitizer Conjugates. Methods in Molecular Biology, 2022, 2451, 505-520.	0.9	0
4	Conjugation of IRDye Photosensitizers or Fluorophores to Nanobodies. Methods in Molecular Biology, 2022, 2451, 495-503.	0.9	1
5	Investigation of the Therapeutic Potential of Nanobody-Targeted Photodynamic Therapy in an Orthotopic Head and Neck Cancer Model. Methods in Molecular Biology, 2022, 2451, 521-531.	0.9	0
6	Nanobody-Targeted Photodynamic Therapy: Nanobody Production and Purification. Methods in Molecular Biology, 2022, 2451, 481-493.	0.9	0
7	Assessment of the In Vivo Response to Nanobody-Targeted PDT Through Intravital Microscopy. Methods in Molecular Biology, 2022, 2451, 533-545.	0.9	0
8	Orthotopic Breast Cancer Model to Investigate the Therapeutic Efficacy of Nanobody-Targeted Photodynamic Therapy. Methods in Molecular Biology, 2022, 2451, 547-556.	0.9	0
9	What NIR photodynamic activation offers molecular targeted nanomedicines: Perspectives into the conundrum of tumor specificity and selectivity. Nano Today, 2021, 36, 101052.	11.9	21
10	Targeting of promising transmembrane proteins for diagnosis and treatment of pancreatic ductal adenocarcinoma. Theranostics, 2021, 11, 9022-9037.	10.0	13
11	Molecular targets for anticancer therapies in companion animals and humans: what can we learn from each other?. Theranostics, 2021, 11, 3882-3897.	10.0	10
12	Vascular targeted photodynamic therapy: A review of the efforts towards molecular targeting of tumor vasculature. , 2021, , 175-186.		0
13	Single Domain Antibodies as Carriers for Intracellular Drug Delivery: A Proof of Principle Study. Biomolecules, 2021, 11, 927.	4.0	2
14	Nanobody-targeted photodynamic therapy for the treatment of feline oral carcinoma: a step towards translation to the veterinary clinic. Nanophotonics, 2021, 10, 3075-3087.	6.0	6
15	Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice. Theranostics, 2021, 11, 5525-5538.	10.0	33
16	Dual Targeting of Endothelial and Cancer Cells Potentiates In Vitro Nanobody-Targeted Photodynamic Therapy. Cancers, 2020, 12, 2732.	3.7	12
17	Endothelial Cell Targeting by cRGD-Functionalized Polymeric Nanoparticles under Static and Flow Conditions. Nanomaterials, 2020, 10, 1353.	4.1	20
18	Dithiolane-Crosslinked Poly(ε-caprolactone)-Based Micelles: Impact of Monomer Sequence, Nature of Monomer, and Reducing Agent on the Dynamic Crosslinking Properties. Macromolecules, 2020, 53, 7009-7024.	4.8	15

SABRINA OLIVEIRA

#	Article	IF	CITATIONS
19	Correlation between in vitro stability and pharmacokinetics of poly(ε-caprolactone)-based micelles loaded with a photosensitizer. Journal of Controlled Release, 2020, 328, 942-951.	9.9	12
20	EGFR-Targeted Nanobody Functionalized Polymeric Micelles Loaded with mTHPC for Selective Photodynamic Therapy. Molecular Pharmaceutics, 2020, 17, 1276-1292.	4.6	43
21	Acute cellular and vascular responses to photodynamic therapy using EGFR-targeted nanobody-photosensitizer conjugates studied with intravital optical imaging and magnetic resonance imaging. Theranostics, 2020, 10, 2436-2452.	10.0	32
22	Preclinical and Clinical Evidence of Immune Responses Triggered in Oncologic Photodynamic Therapy: Clinical Recommendations. Journal of Clinical Medicine, 2020, 9, 333.	2.4	72
23	π-π-Stacked Poly(ε-caprolactone)-b-poly(ethylene glycol) Micelles Loaded with a Photosensitizer for Photodynamic Therapy. Pharmaceutics, 2020, 12, 338.	4.5	6
24	The Potential of Nanobody-Targeted Photodynamic Therapy to Trigger Immune Responses. Cancers, 2020, 12, 978.	3.7	21
25	Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session. Journal of Controlled Release, 2020, 323, 269-281.	9.9	49
26	Patient-Derived Head and Neck Cancer Organoids Recapitulate EGFR Expression Levels of Respective Tissues and Are Responsive to EGFR-Targeted Photodynamic Therapy. Journal of Clinical Medicine, 2019, 8, 1880.	2.4	64
27	Nanobody-Targeted Photodynamic Therapy Selectively Kills Viral GPCR-Expressing Glioblastoma Cells. Molecular Pharmaceutics, 2019, 16, 3145-3156.	4.6	61
28	VHH-Photosensitizer Conjugates for Targeted Photodynamic Therapy of Met-Overexpressing Tumor Cells. Antibodies, 2019, 8, 26.	2.5	28
29	Imaging of Tumor Spheroids, Dual-Isotope SPECT, and Autoradiographic Analysis to Assess the Tumor Uptake and Distribution of Different Nanobodies. Molecular Imaging and Biology, 2019, 21, 1079-1088.	2.6	22
30	Selective Cytotoxicity to HER2 Positive Breast Cancer Cells by Saporin-Loaded Nanobody-Targeted Polymeric Nanoparticles in Combination with Photochemical Internalization. Molecular Pharmaceutics, 2019, 16, 1633-1647.	4.6	49
31	Vascular targeted photodynamic therapy: A review of the efforts towards molecular targeting of tumor vasculature. Journal of Porphyrins and Phthalocyanines, 2019, 23, 1229-1240.	0.8	23
32	Understanding the first steps towards immune-modulation triggered by nanobody-targeted photodynamic therapy (Conference Presentation). , 2019, , .		0
33	Insights into maleimide-thiol conjugation chemistry: Conditions for efficient surface functionalization of nanoparticles for receptor targeting. Journal of Controlled Release, 2018, 282, 101-109.	9.9	91
34	Epidermal growth factor receptor (EGFR) density may not be the only determinant for the efficacy of EGFRâ€ŧargeted photoimmunotherapy in human head and neck cancer cell lines. Lasers in Surgery and Medicine, 2018, 50, 513-522.	2.1	19
35	Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study. Clinical Cancer Research, 2017, 23, 2730-2741.	7.0	212
36	Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast Cancer. Cancer Research, 2017, 77, 623-631.	0.9	34

SABRINA OLIVEIRA

#	Article	IF	CITATIONS
37	Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions. Cancers, 2017, 9, 19.	3.7	694
38	Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors. Frontiers in Immunology, 2017, 8, 1287.	4.8	181
39	EGFR targeted nanobody–photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer. Journal of Controlled Release, 2016, 229, 93-105.	9.9	132
40	Optical imaging of pre-invasive breast cancer with a combination of VHHs targeting CAIX and HER2 increases contrast and facilitates tumour characterization. EJNMMI Research, 2016, 6, 14.	2.5	43
41	Hypoxia-Targeting Fluorescent Nanobodies for Optical Molecular Imaging of Pre-Invasive Breast Cancer. Molecular Imaging and Biology, 2016, 18, 535-544.	2.6	54
42	Site-specific conjugation of single domain antibodies to liposomes enhances photosensitizer uptake and photodynamic therapy efficacy. Nanoscale, 2016, 8, 6490-6494.	5.6	37
43	Nanobody-based cancer therapy of solid tumors. Nanomedicine, 2015, 10, 161-174.	3.3	204
44	Characterization and Evaluation of the Artemis Camera for Fluorescence-Guided Cancer Surgery. Molecular Imaging and Biology, 2015, 17, 413-423.	2.6	37
45	Nanobody-targeted photodynamic therapy for oncology. Photodiagnosis and Photodynamic Therapy, 2015, 12, 339.	2.6	2
46	Intraoperative fluorescence delineation of head and neck cancer with a fluorescent Antiâ€epidermal growth factor receptor nanobody. International Journal of Cancer, 2014, 134, 2663-2673.	5.1	76
47	Capillary electrophoresis-based assessment of nanobody affinity and purity. Analytica Chimica Acta, 2014, 818, 1-6.	5.4	17
48	Nanobody–photosensitizer conjugates for targeted photodynamic therapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 1441-1451.	3.3	76
49	Abstract 4935: Hypoxia targeting fluorescent nanobodies for optical molecular imaging of preinvasive breast cancer. , 2014, , .		0
50	Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1718-1729.	6.4	109
51	Inhibition of Tumor Growth by Targeted Anti-EGFR/IGF-1R Nanobullets Depends on Efficient Blocking of Cell Survival Pathways. Molecular Pharmaceutics, 2013, 10, 3717-3727.	4.6	26
52	Molecular imaging with a fluorescent antibody targeting carbonic anhydrase IX can successfully detect hypoxic ductal carcinoma in situ of the breast. Breast Cancer Research and Treatment, 2013, 140, 263-272.	2.5	21
53	Targeting tumors with nanobodies for cancer imaging and therapy. Journal of Controlled Release, 2013, 172, 607-617.	9.9	172
54	Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy. Biomaterials, 2013, 34, 1255-1260.	11.4	111

SABRINA OLIVEIRA

#	Article	IF	CITATIONS
55	Rapid Visualization of Human Tumor Xenografts through Optical Imaging with a Near-Infrared Fluorescent Anti–Epidermal Growth Factor Receptor Nanobody. Molecular Imaging, 2012, 11, 7290.2011.00025.	1.4	152
56	121 Tumor-targeted Nanobullets for Anti-cancer Combination Therapy. European Journal of Cancer, 2012, 48, 38.	2.8	0
57	A novel method to quantify IRDye800CW fluorescent antibody probes ex vivo in tissue distribution studies. EJNMMI Research, 2012, 2, 50.	2.5	49
58	Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment. Journal of Controlled Release, 2012, 159, 281-289.	9.9	83
59	Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody. Molecular Imaging, 2012, 11, 33-46.	1.4	88
60	Nanobody — Shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting. Journal of Controlled Release, 2011, 151, 183-192.	9.9	94
61	Reprint of "Nanobody — Shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting". Journal of Controlled Release, 2011, 153, 93-102.	9.9	29
62	Downregulation of EGFR by a novel multivalent nanobody-liposome platform. Journal of Controlled Release, 2010, 145, 165-175.	9.9	117
63	Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies. Drug Discovery Today, 2010, 15, 102-114.	6.4	45
64	Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy. Current Cancer Drug Targets, 2009, 9, 748-760.	1.6	165
65	Delivery of siRNA to the Target Cell Cytoplasm: Photochemical Internalization Facilitates Endosomal Escape and Improves Silencing Efficiency, In Vitro and In Vivo. Current Pharmaceutical Design, 2008, 14, 3686-3697.	1.9	43
66	Photochemical internalization enhances silencing of epidermal growth factor receptor through improved endosomal escape of siRNA. Biochimica Et Biophysica Acta - Biomembranes, 2007, 1768, 1211-1217.	2.6	86
67	Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes. International Journal of Pharmaceutics, 2007, 331, 211-214.	5.2	145
68	Sensitive Spectroscopic Detection of Large and Denatured Protein Aggregates in Solution by Use of the Fluorescent Dye Nile Red. Journal of Fluorescence, 2007, 17, 181-192.	2.5	67
69	Targeted Delivery of siRNA. Journal of Biomedicine and Biotechnology, 2006, 2006, 1-9.	3.0	62
70	Molecular biology of epidermal growth factor receptor inhibition for cancer therapy. Expert Opinion on Biological Therapy, 2006, 6, 605-617.	3.1	54